These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 15624894)

  • 41. Voriconazole-induced phototoxicity masquerading as chronic graft-versus-host disease of the skin in allogeneic hematopoietic cell transplant recipients.
    Patel AR; Turner ML; Baird K; Gea-Banacloche J; Mitchell S; Pavletic SZ; Wise B; Cowen EW
    Biol Blood Marrow Transplant; 2009 Mar; 15(3):370-6. PubMed ID: 19203729
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Experience with voriconazole in invasive aspergillosis].
    Thiel E; Schwartz S
    Mycoses; 2003; 46 Suppl 2():3-7. PubMed ID: 15055137
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [New systemic antifungal drugs: mechanisms of action, drug interactions and side effects].
    Schäfer-Korting M
    Mycoses; 2003; 46 Suppl 1():28-31. PubMed ID: 12955850
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Case collection study of the safety of AmBisome in association with voriconazole in the treatment of patients with invasive fungal infection.
    Askari E; Jarque I; Nicolás Franco S; Cáceres Agra JJ
    Rev Esp Quimioter; 2010 Dec; 23(4):210-2. PubMed ID: 21191561
    [No Abstract]   [Full Text] [Related]  

  • 45. [Case of pulmonary aspergillosis associated with inappropriate antidiuretic hormone syndrome caused by voriconazole therapy].
    Isobe K; Muraoka S; Sugino K; Yamazaki Y; Kikuchi N; Hamanaka N; Takai Y; Shimizu K; Kimura K; Hiroi N; Shibuya K; Homma S
    Nihon Kokyuki Gakkai Zasshi; 2007 Jun; 45(6):489-93. PubMed ID: 17644946
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical outcomes of lung-transplant recipients treated by voriconazole and caspofungin combination in aspergillosis.
    Thomas A; Korb V; Guillemain R; Caruba T; Boussaud V; Billaud E; Prognon P; Begué D; Sabatier B
    J Clin Pharm Ther; 2010 Feb; 35(1):49-53. PubMed ID: 20175811
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Persistent photopsia following course of oral voriconazole.
    Kadikoy H; Barkmeier A; Peck B; Carvounis PE
    J Ocul Pharmacol Ther; 2010 Aug; 26(4):387-8. PubMed ID: 20653481
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Voriconazole-associated myositis.
    Shanmugam VK; Matsumoto C; Pien E; Rosen J; Kumar P; Whelton S; Steen V
    J Clin Rheumatol; 2009 Oct; 15(7):350-3. PubMed ID: 20009971
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Voriconazole in clinical practice.
    Mikulska M; Novelli A; Aversa F; Cesaro S; de Rosa FG; Girmenia C; Micozzi A; Sanguinetti M; Viscoli C
    J Chemother; 2012 Dec; 24(6):311-27. PubMed ID: 23174096
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Voriconazole-induced blistering in the setting of graft versus host disease: A report of 2 patients.
    Conlon JD; Dauenhauer M; Tonkovic-Capin V; Talano J; Margolis D; Drolet BA; Fairley JA
    J Am Acad Dermatol; 2008 Mar; 58(3):484-7. PubMed ID: 18280346
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Voriconazole treatment for less-common, emerging, or refractory fungal infections.
    Perfect JR; Marr KA; Walsh TJ; Greenberg RN; DuPont B; de la Torre-Cisneros J; Just-Nübling G; Schlamm HT; Lutsar I; Espinel-Ingroff A; Johnson E
    Clin Infect Dis; 2003 May; 36(9):1122-31. PubMed ID: 12715306
    [TBL] [Abstract][Full Text] [Related]  

  • 52. An investigation of visual hallucinations associated with voriconazole administration to patients with hematological malignancies.
    Sakurada H; Yasuhara K; Kato K; Asano S; Yoshida M; Yamamura M; Tachi T; Teramachi H
    Pharmazie; 2016 Nov; 71(11):660-664. PubMed ID: 29441972
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Torsades de pointes associated with voriconazole use.
    Philips JA; Marty FM; Stone RM; Koplan BA; Katz JT; Baden LR
    Transpl Infect Dis; 2007 Mar; 9(1):33-6. PubMed ID: 17313469
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Voriconazole-associated phototoxicity.
    Riahi RR; Cohen PR
    Dermatol Online J; 2011 Feb; 17(2):15. PubMed ID: 21382298
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial.
    Park WB; Kim NH; Kim KH; Lee SH; Nam WS; Yoon SH; Song KH; Choe PG; Kim NJ; Jang IJ; Oh MD; Yu KS
    Clin Infect Dis; 2012 Oct; 55(8):1080-7. PubMed ID: 22761409
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis.
    Sambatakou H; Dupont B; Lode H; Denning DW
    Am J Med; 2006 Jun; 119(6):527.e17-24. PubMed ID: 16750972
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Role of voriconazole in critically ill patients with invasive mycoses].
    Alvarez Lerma F
    Rev Iberoam Micol; 2007 Sep; 24(3):209-12. PubMed ID: 17874857
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis.
    Denning DW; Ribaud P; Milpied N; Caillot D; Herbrecht R; Thiel E; Haas A; Ruhnke M; Lode H
    Clin Infect Dis; 2002 Mar; 34(5):563-71. PubMed ID: 11807679
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacokinetic/pharmacodynamic profile of voriconazole.
    Theuretzbacher U; Ihle F; Derendorf H
    Clin Pharmacokinet; 2006; 45(7):649-63. PubMed ID: 16802848
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A case of pseudomembranous colitis after voriconazole therapy.
    Kwon JC; Kang MK; Kim SH; Choi SM; Kim HJ; Min WS; Lee DG
    Yonsei Med J; 2011 Sep; 52(5):863-5. PubMed ID: 21786455
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.